Introduction {#s1}
============

Chronic liver injury is a major cause of morbidity and mortality in the US and worldwide, due to complications of liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC) [@pone.0092925-Starr1]. To date, there are no effective treatments for patients with liver fibrosis, so a better understanding of pathways that regulate fibrosis has great clinical potential [@pone.0092925-Bataller1]. Many inflammatory cytokines and growth factors are released during liver injury, including platelet derived growth factors (PDGFs), which are potent mitogens for hepatic stellate cells (HSCs) [@pone.0092925-Bataller1], [@pone.0092925-HernandezGea1]. The PDGF family of ligands and receptors plays a central role in repair after injury, and are key regulators of the formation of connective tissue [@pone.0092925-Pierce1], [@pone.0092925-Olson1]. Elevated platelet-derived growth factor receptor (PDGFR) expression is detected in human heart disease, pulmonary fibrosis, and kidney fibrosis [@pone.0092925-Chong1]--[@pone.0092925-Floege1], and blocking PDGFR signaling decreases collagen deposition after myocardial infarct, in pulmonary fibrosis, and in kidney fibrosis [@pone.0092925-Zymek1]--[@pone.0092925-Chen1]. Thus, targeting the PDGF pathway may modulate liver fibrosis.

There are five known functional ligand dimers in the PDGF family, -AA, -AB, -BB, -CC, and --DD, which bind cell surface receptor tyrosine kinases comprised of PDGFRα and PDGFRβ subunits [@pone.0092925-Andrae1]. PDGFs stimulate the migration and proliferation of mesenchymal cells during development [@pone.0092925-Hoch1]. Loss of PDGFRs leads to significant abnormalities in mice [@pone.0092925-Soriano1], [@pone.0092925-Soriano2]. PDGFRβ is critical to vascular and hematopoietic development, and cell specific deletion or activation of PDGFRβ results in failure or increased pericyte and vascular smooth muscle cell coverage of blood vessels in mice [@pone.0092925-Soriano1], [@pone.0092925-Mellgren1], [@pone.0092925-Olson2]. PDGFRα is required for migration and survival of neural crest cells and for skeletal development, and cell specific deletion of PDGFRα decreases β-cell proliferation in the pancreas and ventricular septation of the heart [@pone.0092925-Soriano2], [@pone.0092925-Chen2], [@pone.0092925-Tallquist1]. Constitutive activation of PDGFRα causes fibrosis that is particularly noticeable in intestine, skin, muscle and heart, but activation has to be conditionally induced in late prenatal or adult animals, as constitutive PDGFRα activation causes lethality [@pone.0092925-Olson1]. Deleting one allele of *Pdgfrα* in mice does not affect development, unlike the observed phenotype in homozygous knockout mice [@pone.0092925-Soriano2], [@pone.0092925-Hamilton1]. PDGF signal transduction pathways play a prominent role in fibrosis [@pone.0092925-Bonner1]. It has been suggested that PDGFRα signaling is more likely to induce fibrosis than PDGFRβ [@pone.0092925-Iwayama1], however this notion has not been conclusively demonstrated in the liver. In summary, PDGF signaling is tightly regulated by abundance and degree of signal transduction, and perturbing either results in developmental defects and organ dysfunction.

In the present study we analyzed *PDGFR* in human liver disease, human liver cell lines, and a mouse model of liver injury and fibrosis. We found increased PDGFRα in human liver specimens with fibrosis and cirrhosis. PDGFRα is primarily expressed in HSCs, and *Pdgfrα* expression increased in injured mouse livers. We investigated the role of PDGFRα in liver fibrosis using mice with only one allele of *Pdgfrα*, and found that reducing *Pdgfrα* copy number inhibits liver fibrosis in mice. Together our data suggest that PDGFRα inhibitors could be an effective means to reduce liver fibrosis in patients.

Materials and Methods {#s2}
=====================

Animals {#s2a}
-------

Mice were housed in a specific pathogen-free environment overseen by the Department of Comparative Medicine at the University of Washington with IACUC approval under protocol \#4295-01. Mice that express nuclear localized green fluorescent protein (GFP) driven by the endogenous *Pdgfrα* promoter, *Pdgfrα^nGFP^*, were purchased from the Jackson Laboratory (007669) [@pone.0092925-Hamilton1]. Either wild type (WT) littermates that retain both *Pdgfrα* alleles, or control mice, *i.e.* male C57BL/6 mice purchased from the Jackson Laboratory (000664), were used as experimental controls. To induce fibrosis, mice were injected (*i.p*.) with 10 μl/g body weight CCl~4~ (Sigma-Aldrich) diluted in olive oil 10% (v/v), either one time (acute injury) or twice weekly for four or six weeks (chronic injury). Olive oil-injected animals served as controls for CCl~4~-injected mice. Animals were sacrificed using CO~2~ inhalation. The Institutional Animal Care and Use Committee of the University of Washington, which is certified by the Association for Assessment and Accreditation of Laboratory Animal Care International, approved all experiments.

Human Liver Samples {#s2b}
-------------------

Human liver and HCC specimens were obtained from the University of Washington Medical Center after IRB-approval. IHC was performed on liver specimens from patients with cirrhosis who underwent liver transplantation surgery at the University of Washington Medical Center from 1989 to 2002, HSD \#23602 (MMY) [@pone.0092925-Yeh1]. Immunoblot analysis was performed on resected liver specimens collected after receiving informed consent IRB \#31281 (RSY). All samples were de-identified of any patient information. Specimens were either fixed in formalin or frozen at −80°C until use.

Immunohistochemistry (IHC) and Histological Staining {#s2c}
----------------------------------------------------

Formalin-fixed liver tissue was processed and embedded in paraffin using standard protocols, and IHC was performed as previously described [@pone.0092925-Campbell1], using the primary antibodies listed in [Table S1](#pone.0092925.s003){ref-type="supplementary-material"}. A board-certified clinical liver pathologist (MMY) reviewed all human samples and determined the presence of cirrhosis and/or tumor and assessed for PDGFRα and PDGFRβ immunoreactivity. To quantify fibrosis, formalin-fixed liver tissue was stained with picrosirius red. For morphometric analysis, picrosirius red area was imaged under polarized light [@pone.0092925-Junqueira1]. Images were analyzed using NIH image J software to convert pixels to binary values and determine the relative number of positive and negative pixels.

Immunoblotting {#s2d}
--------------

Tissues were homogenized in a 1% Triton-x 100 lysis buffer and processed as described [@pone.0092925-Campbell2]. Membranes were incubated with primary antibodies overnight at 4°C, and then with the appropriate horseradish peroxidase (HRP)-conjugated secondary antibodies. Primary antibodies used in this study are listed in [Table S1](#pone.0092925.s003){ref-type="supplementary-material"}.

Immunofluorescence (IF) and *ex-vivo* Imaging {#s2e}
---------------------------------------------

Livers were fixed in 4% paraformaldehyde overnight, and tissues were frozen in optimum cutting temperature compound for cryosectioning. IF was performed using standard techniques, with liver sections incubated overnight with the primary antibodies listed in [Table S1](#pone.0092925.s003){ref-type="supplementary-material"}. Immune complexes were detected with goat Alexa 633 conjugated anti-rat IgG (A-21094, Life Technologies) and goat Alexa 546 conjugated anti-rabbit IgG (A-11010, Life Technologies) antibodies. Sections were mounted with SlowFade Gold (S36936, Life Technologies) and imaged with a Leica SL confocal microscope (Leica Microsystems, Keck Center UW). For *ex-vivo* imaging, freshly harvested livers were analyzed as previously described [@pone.0092925-Wright1]. Images were captured using a Zeiss 510 Meta confocal microscope. In *Pdgfrα^WT/nGFP^* mice, GFP fluorescence was used to report PDGFRα positive cells [@pone.0092925-Hamilton1].

Cell Culture and Proliferation Assay {#s2f}
------------------------------------

Liver cell lines ([Table S2](#pone.0092925.s004){ref-type="supplementary-material"}) were grown in a 37°C incubator with 95% humidity and 5% CO2 in DMEM (Life Technologies) with 10% FBS. Confluent cells were split and allowed to attach to plates as described [@pone.0092925-Argast1]. Cells were serum-starved for 24 hours then stimulated with 10 ng/ml PDGF-AA, -AB,-BB, or --CC (R&D systems) for 24 hours. \[^3^H\]Thymidine (1 μCi/ml final concentration) was added to the media for the final 3 hours of stimulation. Unincorporated \[^3^H\] thymidine was removed from the cells, and trichloroacetic acid was used to precipitate protein-bound DNA. DNA was solubilized in NaOH, quantified using a scintillation counter, and measured in triplicate.

RNA Expression Analysis {#s2g}
-----------------------

RNA was extracted from cells or liver tissue using Trizol (15596-018, Life Technologies) as described by the manufacturer. Reactions contained cDNA synthesized from 0.5 μg RNA using MMLV (28025-013, Life Technologies), and Taqman Universal Mastermix II (4440040, Life Technologies). Cycling conditions were 95°C for 10 min, and 49 cycles of 95°C for 15 sec, 60°C for 60 sec with a final extension at 72°C for 1 min. Data are represented as delta delta Ct values after normalization to *Gapdh* mRNA levels. Primers used in this experiment are listed in [Table S3](#pone.0092925.s005){ref-type="supplementary-material"}.

Statistical Analysis {#s2h}
--------------------

Statistical significance was analyzed using Prism software (Graphpad), either with Kruskal-Wallis non-parametric ANOVA with significance p\<0.05, or Mann-Whitney U test with significance p\<0.05, as indicated in the figure legends.

Results {#s3}
=======

Expression of PDGFRα in Human Cirrhosis and HCC {#s3a}
-----------------------------------------------

Previous studies have demonstrated that over expression of PDGF ligands induces fibrosis in mice [@pone.0092925-Thieringer1]--[@pone.0092925-Campbell3], and elevated expression of *PDGFRβ* in chronic liver disease has been reported [@pone.0092925-Ikura1]--[@pone.0092925-Pinzani1]. As PDGF ligands can activate both PDGFRα and PDGFRβ, we sought to investigate the role of PDGFRα in chronic liver injury. 80--90% of human HCC arise in the setting of a cirrhotic liver, in which HSCs have been activated [@pone.0092925-Tiribelli1], so we first performed IHC analysis to determine whether PDGFRα and PDGFRβ levels are elevated in human cirrhosis and HCC. Fibrotic and cirrhotic livers had focal perisinusoidal immunoreactivity for PDGFRα, which was stronger in steatotic and cirrhotic livers, while normal adult liver had relatively little PDGFRα immunoreactivity ([Figure 1 A--D](#pone-0092925-g001){ref-type="fig"}). PDGFRβ immunoreactivity was also increased in the fibrotic and cirrhotic areas compared to un-injured liver (data not shown). [Table S4](#pone.0092925.s006){ref-type="supplementary-material"} summarizes PDGFRα and PDGFRβ immunoreactivity in diseased human liver specimens, 77% of which demonstrated increased PDGFRα immunoreactivity and 56% of which demonstrated increased PDGFRβ immunoreactivity. Using a separate set of specimens, we compared PDGFR protein levels in grossly dissected HCC tumors to those of adjacent non-tumor livers from the same patients by immunoblot analysis. PDGFRα protein was frequently detected in the non-tumor tissue ([Figure S1](#pone.0092925.s001){ref-type="supplementary-material"}, [Table S5](#pone.0092925.s007){ref-type="supplementary-material"}). One specimen, patient 5, had detectable PDGFRα protein by immunoblot in the tumor ([Table S5](#pone.0092925.s007){ref-type="supplementary-material"}). IHC analysis of this specimen demonstrated PDGFRα immunoreactive cells within the tumor ([Figure 1 E, F](#pone-0092925-g001){ref-type="fig"}), but these cells did not have the histological appearance of hepatocytes, suggesting that non-parenchymal cells (NPCs) had invaded the parenchymal tumor and account for the PDGFRα immunoreactivity observed in this tumor by immunoblot analysis. Taken together, our data suggest that PDGFRα is expressed primarily in fibrotic and cirrhotic livers, predominantly in NPCs.

![Perisinusoidal PDGFRα expression is localized to fibrotic or cirrhotic areas in tumor specimens by IHC.\
A) Uninjured (non-diseased) human liver demonstrate focal PDGFRα immunoreactivity (arrow) in NPCs but not hepatocytes. Resected tumor specimens show PDGFRα positive cells within fibrotic areas (arrow) (B), and cirrhotic areas (C), with sinusoidal PDGFRα immunoreactivity (arrows) within fibrotic septa (D). E and F) A resected tumor specimen shows stromal PDGFRα immunoreactivity (arrows). All scale bars are 50 μm.](pone.0092925.g001){#pone-0092925-g001}

Expression of PDGFRα and PDGFRβ in Human Liver and Stellate Cell Lines {#s3b}
----------------------------------------------------------------------

We next analyzed mRNA transcripts from human liver cell lines, and found that both *PDGFRα* and *PDGFRβ* mRNA are expressed in non-diseased human liver ([Figure 2](#pone-0092925-g002){ref-type="fig"}), but that the human HSC line LX-1 has a significantly higher relative expression of *PDGFRα* ([Figure 2A](#pone-0092925-g002){ref-type="fig"}). LX-2 cells, a LX-1 subclone, express *PDGFRβ,* albeit to variable levels, and LX-1 cells express little to no *PDGFRβ* ([Figure 2B](#pone-0092925-g002){ref-type="fig"}). Transcription of both PDGFRs is reduced in human hepatoma cell lines compared to whole liver, suggesting that PDGFRs are predominantly expressed in NPCs. We next stimulated various cell lines with PDGF ligands, and found that PDGF -AA, -AB, -BB, and --CC lead to robust proliferation in stellate cells, but these ligands had little effect on the hepatocyte or hepatoma cell lines tested ([Table S6](#pone.0092925.s008){ref-type="supplementary-material"}).

![PDGF receptors are expressed in hepatic stellate cell lines.\
A) Relative *PDGFRα* mRNA expression is greater in LX1 HSCs compared to LX2 and hepatocyte cell lines. B) *PDGFRβ* mRNA expression in LX2 HSC is variable, but similar to whole liver and hepatocyte cell lines. *PDGFR* expression was normalized to 18S ribosomal RNA and reported as fold increase by the ΔΔCt method, normalized to adult human liver. Error bars indicate standard error of the mean, n = 3 separate cultures.](pone.0092925.g002){#pone-0092925-g002}

Increased Expression of *Pdgfrα* and *Pdgfrβ* in Mice after CCl~4~ induced Hepatocyte Injury {#s3c}
--------------------------------------------------------------------------------------------

To investigate the role of PDGFRα in liver injury and fibrosis, we used the well-established model of CCl~4~ injection, in which HSCs are activated in response to necroinflammatory injury to hepatocytes [@pone.0092925-Weber1]. CCl~4~ injury to rats has been shown to induce *Pdgfrs* mRNA in the liver [@pone.0092925-BorkhamKamphorst1]. To determine whether *Pdgfr* expression is induced after liver injury in mice, WT mice were injected with a single dose of CCl~4~. We found that *Pdgfrα* expression increased during 72 hours after injury ([Figure 3A](#pone-0092925-g003){ref-type="fig"}). CCl~4~ injection also induced expression of *Pdgfrβ*, although to a differing extent and with a different time course than *Pdgfrα* ([Figure 3B](#pone-0092925-g003){ref-type="fig"}). Thus, acute CCl~4~ exposure induces *Pdgfr* expression in the liver.

![PDGFR mRNA expression increases in response to acute CCl~4~ exposure.\
Expression of *Pdgfrα* (A) and *Pdgfrβ* (B) increases after a single injection of CCl~4~ in C57BL/6 mice. Values are represented as means with SEM; n = 3 mice per group; and data was analyzed by Kruskal-Wallis non-parametric ANOVA \* = p\<0.05.](pone.0092925.g003){#pone-0092925-g003}

Cells Expressing Pdgfrα and Pdgfrβ Respond to CCl~4~ Injury {#s3d}
-----------------------------------------------------------

To determine the liver cell type that expresses PDGFRα in response to liver injury, we used transgenic *Pdgfrα^WT/nGFP^* mice, in which the endogenous *Pdgfrα* promoter initiates transcription of nuclear-restricted GFP reporter in place of the *Pdgfrα* gene [@pone.0092925-Hamilton1]. These mice have one copy of *Pdgfrα* replaced by GFP and are thus heterozygous for *Pdgfrα*. While a single injection of CCl~4~ induces necrosis and injury that is repaired within seven days, repeated injection of CCl~4~ induces liver fibrosis [@pone.0092925-Weber1]. Vehicle-injected *Pdgfrα^WT/nGFP^* mice have histologically normal liver ([Figure 4A](#pone-0092925-g004){ref-type="fig"}). A single CCl~4~ injection increases the density of small cells with a high nuclear to cytoplasmic ratio, suggestive of inflammatory cells, around central veins at 72 hours, while chronic injection increases the density of cells between portal veins ([Figure 4B, C](#pone-0092925-g004){ref-type="fig"}). As shown in [Figure 4D](#pone-0092925-g004){ref-type="fig"}, vehicle-injected *Pdgfrα^WT/nGFP^* mice have an even distribution of PDGFRα-positive cells throughout the liver lobule. 72 hours after a single injection of CCl~4~, however, PDGFRα-positive cells have a higher density around central veins at areas of hepatocyte injury ([Figure 4E](#pone-0092925-g004){ref-type="fig"}). We found that after six weeks of twice weekly CCl~4~ injections, PDGFRα positive cells are detected around and between portal veins, where fibrotic bands form ([Figure 4F](#pone-0092925-g004){ref-type="fig"}). As PDGFRβ is expressed in quiescent and activated HSCs [@pone.0092925-Breitkopf1], we next determined whether both PDGFRs are expressed in the same cell type. PDGFRα positive cells in chronic CCl~4~ injected *Pdgfrα^WT/nGFP^*mouse livers ([Figure 5A, D](#pone-0092925-g005){ref-type="fig"}) co-localize with PDGFRβ immunoreactive cells ([Figure 5B, E](#pone-0092925-g005){ref-type="fig"}), indicating that activated HSCs express both receptors ([Figure 5C, F](#pone-0092925-g005){ref-type="fig"}) after chronic CCl~4~ injection.

![PDGFRα positive cells form fibrotic bands after chronic CCl~4~ injection in *Pdgfrα^WT/nGFP^* mice.\
Oil injection A) does not lead to necrosis around central veins (CV), while areas of necrosis are visible (arrow) 72 hrs after CCl~4~ injection (B) as determined by H&E. C) NPCs are visible in areas between portal veins (PV, arrow). D) PDGFRα positive cells (green nuclei) are evenly distributed throughout the liver after oil injection. E) PDGFRα positive cells localize around the CV 72 hr after CCl~4~ injury. F) PDGFRα positive cells align with fibrotic bands that develop between portal triads after chronic CCl~4~ injury. Scale bars are 100 μm.](pone.0092925.g004){#pone-0092925-g004}

![PDGFRα-positive cells co-localize with PDGFRβ-positive cells in chronic CCl~4~ injured liver.\
*Pdgfrα^WT/nGFP^* mice were injected with CCl~4~ twice weekly for six weeks. PDGFRα-expressing cells are identified by nuclear-localized GFP (green). PDGFRβ-expressing cells are identified by IF (PDGFRβ; magenta). A) PDGFRα-positive cells are aligned between portal veins (PV). B) PDGFRβ is expressed in the same periportal area as PDGFRα-positive cells, as shown in the merged image (C). A--C) Scale bars are 100 μm. D--F) Higher magnification shows that PDGFRα and PDGFRβ co-localize in the same cell, based upon co-localization of the GFP and PDGFRβ signal. Scale bars are 10 μm.](pone.0092925.g005){#pone-0092925-g005}

Our data from human tissue using IHC ([Figure 1](#pone-0092925-g001){ref-type="fig"}) and from mice using a GFP reporter ([Figure 5](#pone-0092925-g005){ref-type="fig"}) indicated that HSCs are the predominant liver cell type that expresses PDGFRα. In order to confirm these findings, we stained for specific liver cell epitopes using IF in combination with nuclear-GFP expression in *Pdgfrα^WT/nGFP^*mice [@pone.0092925-Hamilton1]. Images of livers from *Pdgfrα^WT/nGFP^*mice indicate that PDGFRα and PDGFRβ co-localize in the same cells ([Figure 5](#pone-0092925-g005){ref-type="fig"}, [Figure S2A](#pone.0092925.s002){ref-type="supplementary-material"}), and that these cells also express desmin ([Figure S2B](#pone.0092925.s002){ref-type="supplementary-material"}) and cellular retinol binding protein 1 (CRBP-1, [Figure S2C](#pone.0092925.s002){ref-type="supplementary-material"}), proteins expressed in HSCs. Furthermore, GFP is not detected in Kupffer cells that express F4/80 expression ([Figure S2D](#pone.0092925.s002){ref-type="supplementary-material"}), or endothelial cells as identified by CD31 expression ([Figure S2E](#pone.0092925.s002){ref-type="supplementary-material"}). Hepatocytes, identified morphologically by fluorescence as described [@pone.0092925-Johnson1], were also negative for GFP ([Figure S2F](#pone.0092925.s002){ref-type="supplementary-material"}). Taken together, these data suggest that HSCs are the primary liver cell type which express PDGFRα and PDGFRβ.

Reducing PDGFRα Expression Reduces Fibrosis in Mice {#s3e}
---------------------------------------------------

After confirming that *Pdgfrα* expression increases with CCl~4~-induced liver injury, and that PDGFRα-positive HSCs are activated by CCl~4~ exposure, we utilized *Pdgfrα^WT/nGFP^*mice to evaluate the functional significance of *Pdgfrα* expression during liver fibrosis. *Pdgfrα^WT/nGFP^*mice, which are heterozygous for *Pdgfrα* expression, are phenotypically normal [@pone.0092925-Hamilton1] and have normal liver architecture ([Figure 4A](#pone-0092925-g004){ref-type="fig"}). Uninjured and CCl~4~-injected *Pdgfrα^WT/nGFP^* and C57BL/6 mice were analyzed for transcriptional changes in genes associated with chronic liver injury. At baseline and after 4 weeks of twice weekly injections of CCl~4~, *Pdgfrα* expression is decreased in *Pdgfrα^WT/nGFP^* mice compared to C57BL/6 mice ([Figure 6A](#pone-0092925-g006){ref-type="fig"}). *Pdgfrβ* expression was equivalently expressed in both genotypes of uninjured and chronic CCl~4~ injected mice ([Figure 6B](#pone-0092925-g006){ref-type="fig"}). Expression of smooth muscle α-actin (*Acta2*), an epitope that is upregulated when HSCs are activated [@pone.0092925-Rockey1], [@pone.0092925-Yamaoka1], increased when C57BL/6 mice were injected with CCl~4~ for 4 weeks, but *Pdgfrα^WT/nGFP^* mice had greatly reduced *Acta2* expression after chronic liver injury ([Figure 6C](#pone-0092925-g006){ref-type="fig"}). Fibrillar collagen 1a1 (*Col1a1*) expression was equivalent in uninjured mice of the two genotypes, but significantly reduced in chronically injured *Pdgfrα^WT/nGFP^* mice ([Figure 6D](#pone-0092925-g006){ref-type="fig"}). Conversely, collagen 4 (*Col4,* [Figure 6E](#pone-0092925-g006){ref-type="fig"}) and tissue inhibitor of metalloproteinase 1 (*Timp1,* [Figure 6F](#pone-0092925-g006){ref-type="fig"}) expression was increased after chronic CCl~4~ exposure, but was not significantly reduced in *Pdgfrα^WT/nGFP^* mice compared to wild type mice.

![Compared to C57BL/6 mice, chronically CCl~4~ injured *Pdgfrα^WT/nGFP^* mice have reduced transcription of fibrotic genes.\
Livers from *Pdgfrα^WT/nGFP^* and C57BL/6 mice that were either uninjured (controls) or treated for 4 weeks with CCl~4~ were used to prepare total liver RNA. A) Compared to C57BL/6 mice, expression of *Pdgfrα* is decreased in *Pdgfrα^WT/nGFP^* mice in uninjured mice and after chronic CCl~4~. B) Expression of *Pdgfrβ* does not differ between C57BL/6 and *Pdgfrα^WT/nGFP^* mice. C) Expression of *Acta2* is increased in uninjured *Pdgfrα^WT/nGFP^* mice compared to C57BL/6 and decreased after chronic CCl~4~ between *Pdgfrα^WT/nGFP^* and C57BL/6 mice. D) Expression of *Col1a1* is similar in uninjured *Pdgfrα^WT/nGFP^* mice compared to C57BL/6 and decreased after chronic CCl~4~ between *Pdgfrα^WT/nGFP^* and C57BL/6 mice. E) Expression of *Col4* is similar in *Pdgfrα^WT/nGFP^* mice compared to C57BL/6 in both uninjured and chronic CCl~4~ injected mice. F) Expression of *Timp1* is increased to a similar level in both genotypes. Samples were processed as described in [figure 2](#pone-0092925-g002){ref-type="fig"}. Values are represented as means with SEM, and were analyzed by Mann-whitney non-parametric U test \* = p\<0.05, n = 3--6 mice per time point.](pone.0092925.g006){#pone-0092925-g006}

Reduced mRNA expression of *Col1a1* in *Pdgfrα^WT/nGFP^* mice after chronic CCl~4~ injection was accompanied by a reduction in liver fibrosis, as assessed by picrosirius red staining, a histochemical assay for tissue fibrosis. C57BL/6 mice injected with vehicle for 4 weeks had little to no fibrosis ([Figure 7A, D](#pone-0092925-g007){ref-type="fig"}), but developed periportal fibrosis after 4 weeks of twice weekly CCl~4~ injections ([Figure 7B, D](#pone-0092925-g007){ref-type="fig"}). Significantly less collagen was deposited in chronically injured *Pdgfrα^WT/nGFP^* mice ([Figure 7C, D](#pone-0092925-g007){ref-type="fig"}). These results demonstrate that liver fibrosis in response to chronic CCl~4~ injection is dependent on normal expression of PDGFRα, and are consistent with the hypothesis that liver fibrosis is regulated in part by PDGFRα ligands.

![Chronically injured *Pdgfrα^WT/nGFP^* mice have less collagen deposition than C57BL/6 mice.\
Mice were injected with olive oil or CCl~4~ twice weekly for 4 weeks and collagen was detected in liver tissue by picrosirius red staining. A) Liver from a mouse injected with oil shows little collagen deposition. B) C57BL/6 mice develop fibrosis (arrow) after 4 weeks of CCl~4~ injections. C) *Pdgfrα^WT/nGFP^* mice develop less fibrosis (arrow) than C57BL/6 mice after 4 weeks of CCl~4~ injections. D) Quantification of picrosirius red positive area. Values are represented as means with SEM, and were analyzed by Mann-Whitney non-parametric U test \* = p\<0.05, n = 3--6 mice per time point. Scale bars are 100 μm.](pone.0092925.g007){#pone-0092925-g007}

Discussion {#s4}
==========

PDGFRs stimulate proliferation, migration, and survival of mesenchymal cells, and increased activation of PDGFRs leads to organ fibrosis [@pone.0092925-Bonner1], [@pone.0092925-Heldin1]. Elevated expression of PDGFRs is associated with liver fibrosis and cirrhosis, so we sought to determine whether PDGFRα regulates liver fibrogenesis using mice that have one allele of *Pdgfrα* (*Pdgfrα^WT/nGFP^*). We found that mice with decreased *Pdgfrα* expression have less liver fibrosis after chronic CCl~4~ injury. In addition, and consistent with the notion that PDGFRα regulates the liver's response to injury, patients with liver disease have elevated expression of PDGFRα and PDGFRβ. In conjunction, GFP localization in *Pdgfrα^WT/nGFP^* mice indicates that PDGFRα-positive HSCs migrate to sites of injury following CCl~4~ injection. These data all suggest that PDGFRα is involved in the activation of HSCs after hepatocyte injury.

PDGFRs are thought to play a central role in activating HSCs and promoting liver fibrosis and cirrhosis [@pone.0092925-Wong1], [@pone.0092925-Pinzani1], [@pone.0092925-Friedman1]; whether PDGFRα and PDGFRβ play independent roles in fibrogenesis is not known. We and others observe that *Pdgfrβ* expression increases in WT mice after acute liver injury by CCl~4~, implicating PDGFRβ in HSC activation. Thus it is surprising that mice which systemically express a hyperactive PDGFRβ allele do not develop more liver fibrosis than WT mice after 4 weeks of CCl~4~ injections [@pone.0092925-Krampert1]. Our data indicate that hepatocyte injury induces *Pdgfrα* expression above uninjured liver in both mice and humans, corroborating previously published studies [@pone.0092925-Pinzani1], [@pone.0092925-BorkhamKamphorst1]. Our results demonstrate that expression of *Pdgfrα* and *Pdgfrβ* are both increased after chronic CCl~4~ liver injury, while reducing *Pdgfrα* copy number reduces *Pdgfrα* expression but not *Pdgfrβ* expression in *Pdgfrα^WT/nGFP^* mice. Reduced *Pdgfrα* expression in *Pdgfrα^WT/nGFP^* mice corrrelates with significantly reduced *Col1a1* and *Acta2* expression, as well as reduced picrosirius red staining, even though *Pdgfrβ* expression remains elevated. PDGFRα and PDGFRβ appear to affect HSCs differentially, despite being co-localized in the same liver cell type. Further studies will be necessary to dissect the receptor-specific contributions of PDGF signaling pathways in HSCs and in liver fibrosis.

Small perturbations in the PDGF signaling pathway, whether due to changes in expression of ligand or receptor, appear to have a large impact on specific diseases. Support for this notion is found in genetic evidence from rodents, which suggests that small changes in PDGFR activity *in vivo* are capable of significantly affecting a cell's function. For example in development, chimerism studies show that both *Pdgfrβ^+/−^* and *Pdgfrα^+/−^* embryonic stem cells are deficient in contributing cells to the embryo [@pone.0092925-Soriano2], [@pone.0092925-Crosby1], and adult mice have a decreased number of progenitor cells in mice heterozygous *Pdgfrs* [@pone.0092925-McKinnon1], [@pone.0092925-Bell1]. Heterozygous *Pdgfrα* mice have been bred to mice with mutations in PDGF ligands [@pone.0092925-Andrae2] or mutations in immediate early genes directly downstream of PDGFRα [@pone.0092925-Schmahl1], resulting in additive effects. However, deletion of one allele of *Pdgfrα* and the resultant heterozygosity does not affect development [@pone.0092925-Soriano2], [@pone.0092925-Hamilton1]. These studies suggest that a single copy of *Pdgfrα* is usually sufficient for development, although under certain circumstances two alleles of *Pdgfrα* are required. In the current study, we found that *Pdgfrα^WT/nGFP^* mice have reduced fibrosis and reduced expression of the profibrotic genes *Acta2* and *Col1a1* after chronic CCl~4~ injury. Our data indicate that in chronic liver injury, PDGFRα plays a critical role in the development of fibrosis, but that other pathways also contribute to fibrogenesis. Expression of *Col4* and *Timp1* were reduced in *Pdgfrα^WT/nGFP^* mice but not to a significant extent, suggesting that expression of these genes could be more reliant on PDGFRα independent pathways, or heterogeneity in populations of HSCs.

We also sought to better define the role of PDGFRα in liver fibrosis by utilizing both human specimens and mouse models. Using a variety of experimental approaches, increased PDGFRα was seen in cirrhotic human livers and in mice with chemically-induced liver fibrosis. Although no preclinical rodent model fully recapitulates human liver fibrosis, there appears to be comparable molecular pathophysiology between humans and mice. We chose to utilize a knock-in mouse model expressing nuclear-GFP driven by the *Pdgfrα* promoter in order to discriminate between cells located in close proximity to each other, specifically different NPC populations in liver sinusoids [@pone.0092925-Hamilton1]. We did not observe nuclear-GFP expression in hepatocytes, Kupffer cells, or LSECs, thus we conclude that the majority of PDGFRα is expressed in HSCs in the mouse liver, consistent with our observation that human liver specimens express PDGFRα primarily in NPCs. Our IHC data are further supported by data from the Human Protein Atlas (<http://www.proteinatlas.org/ENSG00000134853/cancer>), which demonstrates that NPCs are positive for PDGFRα by IHC in both normal liver and HCC [@pone.0092925-Uhlen1].

We and others posit that selectively targeting PDGFRα in liver fibrosis and cirrhosis could reduce the proliferation, migration, and survival of the activated HSCs cells that contribute to collagen deposition. Therapeutic blockade of PDGFRα signaling may have a broad impact in the treatment of liver fibrosis, as four of the five PDGF ligand dimers, PDGF-AA, -AB, -BB, and --CC, bind and activate PDGFRα [@pone.0092925-Andrae1]. Targeting PDGFRβ, on the other hand, would completely inhibit only signal transduction induced by PDGF-DD, and could disrupt necessary functions of PDGFRβ in the liver. Targeting both PDGFRs with multi-kinase inhibitors, such as imatinib or sorafenib, leads to severe off target effects [@pone.0092925-Teo1], [@pone.0092925-Hasinoff1]. The breadth of multi-kinase inhibitor activity thus likely leads to inhibition of beneficial signal transduction, either via PDGFRβ or other kinases. In summary, our data suggest that PDGFRα has a specific role in liver fibrosis in mice and in humans, and suggest that further mechanistic evaluation of PDGFRα function in the liver has the potential to uncover new anti-fibrotic therapies.
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###### 

**Expression of PDGFRs in human liver tumor and non-tumor tissue.** An immunoblot of PDGFRα detects PDGFRα in non-tumor tissue while an immunoblot for PDGFRβ shows protein in both tumor and surrounding tissue. Albumin was used as a loading control.

(TIF)

###### 

Click here for additional data file.

###### 

**HSCs express PDGFRα.** PDGFRα-driven nuclear GFP is expressed in liver cells that are immunoreactive for common HSC markers: A) PDGFRβ (red), B) Desmin (red), and C) cellular retinol binding protein 1 (CRBP-1) (red). PDGFRα and CRBP-1 are not expressed in cells that stain for D) the Kupffer cell marker F4/80 (blue) or E) the endothelial cell marker CD31(blue). F) PDGFRα positive cells (green) are distinct from hepatocytes (yellow). Scale bars are 10 μm.

(TIF)
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Click here for additional data file.
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**Antibodies used in this study.**

(DOCX)
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Click here for additional data file.
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**Human and mouse hepatocyte and stellate cell lines used in this study.** \*references as PMID number.

(DOCX)
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Click here for additional data file.
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**Primers used for real time analysis.**

(DOCX)
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Click here for additional data file.
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**Summary of PDGFRα and PDGFRβ immunoreactivity in human liver specimens.** Resected liver specimens with HCCs were formalin-fixed, paraffin embedded, and evaluated for the presence of cirrhosis and HCC. IHC for PDGFRα and PDGFRβ was performed as described in Materials and Methods. Relative staining intensity is indicated as weak (+), moderate (++), strong (+++), or absent (0).

(DOCX)
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Click here for additional data file.

###### 

**Immunoblot detection of PDGFR expression in macroscopically dissected human tumors and surrounding liver.** HCCs (Tumor) and surrounding liver (Non-Tumor) were macrodissected from patients, frozen, and processed for immunoblot analysis as described in Materials and Methods. Intensity is indicated as present (+) or absent (0).

(DOCX)

###### 

Click here for additional data file.

###### 

**PDGF stimulates proliferation^1^ in stellate cell lines, but not primary hepatocytes or hepatoma cell lines.** *^1^*Cell proliferation was measured by DNA synthesis using tritiated thymidine incorporation [@pone.0092925-Argast1]. The data is the average of three different experiments that were each done in triplicates. Fold change represents the increase when compared to unstimulated cells for each cell line. *^2^"*Positive control" indicates that DNA synthesis was stimulated in each cell line or primary culture with a growth factor previously reported to simulate proliferation. Growth factors used for each cell and the concentrations are as follows: mouse hepatocytes, EGF (20 ng/mL); AML12 cells, EGF (20 ng/mL); NMH cells, HB-EGF (20 ng/mL); rat stellate cells (2G), 1% fetal calf serum; human stellate cells (LX-2), 1% FCS; SK-Hep (human hepatoma cells of endothelial origin), 10% fetal calf sera.

(DOCX)

###### 

Click here for additional data file.
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